2020 Annual Meeting - Combining Radiation and Immunotherapy for GU Malignancies: What Works, What Doesn't and What Next
There is significant interest in the potential of combining immunooncology drugs (IO) with radiotherapy (RT). This session is focused on GU malignancies due the rapid increase in approved agents for treatment of GU malignancies such as bladder and renal cancers and the desire to keep the session focused on real-practice issues. While IO is often used in the metastatic setting, the role of RT in these patients is evolving such that the radiation oncology professional is frequently in the position of providing radiotherapy (whether definitive or palliation) to a patient receiving IO. This course will provide an educational primer on medical approach to applying and managing patients on IO from a medical oncologist’s perspective, and then focus on what the potential role of IO/RT through presentation of current translational research, and finally review clinical experience and pearls/pitfalls about combining RT with IO.
The activity is designed to meet the interests of radiation oncologists, medical oncologists, surgeons, radiation physicists, radiation therapists, pathologists, radiation dosimetrists, nurses, radiation biologists, specialists, and radiation oncology residents.
- Participate in treatment decision-making discussions regarding use of IO therapies and RT for GU malignancies.
- Recognize the common and uncommon effects of IO and how IO interacts with RT.
- Apply the available data regarding risks and potential benefits of combining RT with IO for GU malignancies.
- Karen Autio, MD MSc is employed at Memorial Sloan Kettering Cancer Center and has no financial relationships with a commercial interest.
- Dayssy A. Diaz Pardo, MD, MS is employed at Department of Radiation Oncology, The Ohio State University Wexner Medical Center and has no financial relationships with a commercial interest.
- Josephine Kang, MD, PhD is employed at NewYork-Presbyterian Hospital, Weill Cornell Medicine and has no financial relationships with a commercial interest.
- Jason A. Efstathiou, MD, PhD, FASTRO is employed at Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School and has investment interests from Blue Earth Diagnostics and Taris Biomedical.
The person(s) above served as the developer(s) of this activity. Additionally, the Education and CME/MOC Committees had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
- 1.25 SA-CME
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing medical education for physicians.
The American Society for Radiation Oncology (ASTRO) designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity meets the American Board of Radiology's criteria for a self-assessment activity in the ABR's Maintenance of Certification program. Participation in this course in combination with the successful completion of the corresponding assessment and course evaluation adheres to the guidelines established by the ABR for 1.25 self-assessment credits.
• No refunds, extensions or substitutions will be made for those registrants who, for any reason, were unable to attend or were tardy for the session.
• No credits will be granted and no refunds, exchanges or transfers will be given to those who do not pass.
• ASTRO staff cannot make modifications to your submitted materials.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.